Related Experiment Video
Updated: Sep 25, 2025

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
New Anticoagulants in Neonates, Children, and Adolescents
Susan Halimeh1, Christoph Male2, Ulrike Nowak-Goettl3
1Gerinnungszentrum Rhein Ruhr, Duisburg, North Rhine-Westphalia, Germany.
Insights
Direct oral anticoagulants (DOACs) like dabigatran and rivaroxaban are now recommended for pediatric thrombosis. Recent clinical trials show these medications are safe and effective for children, overcoming limitations of older treatments.
Area of Science:
- Pediatric Hematology
- Cardiovascular Research
- Pharmacology
Background:
- Pediatric thrombosis presents a growing clinical challenge.
- Current anticoagulant therapies in children have notable drawbacks.
- Direct oral anticoagulants (DOACs) offer potential advantages over traditional treatments.
Purpose of the Study:
- To review the latest clinical trial evidence on DOACs for pediatric thrombosis.
- To assess the efficacy and safety of DOACs in pediatric patients.
- To determine if DOACs can be recommended for treating childhood thrombosis.
Main Methods:
- Literature review of clinical trials on DOACs for pediatric thrombosis.
- Analysis of studies published from clinicaltrials.gov.
- Focus on pivotal Phase III studies for treatment recommendations.
Main Results:
- Thirteen current studies with published results were identified.
- Successful Phase III trials for dabigatran and rivaroxaban in pediatric populations were found.
- These trials led to regulatory approval for using these two DOACs in children.
Conclusions:
- Rivaroxaban and dabigatran are now approved for pediatric use in thrombosis.
- These DOACs can be recommended for both prophylaxis and treatment of thrombotic events in children.
- DOACs represent a significant advancement in managing pediatric thrombosis.
Abstract:
Thrombotic events are an increasing challenge in pediatrics. Standard-of-care anticoagulants for pediatric thrombosis have several disadvantages which could be overcome by using direct oral anticoagulants (DOACs). Until recently, there was not enough evidence from clinical trials to recommend for or against the use of any of the four DOACs in children with thrombosis. In this literature review, we looked at the latest clinical trials in this field. On clinicaltrials.gov, we found 13 current studies with published results. For two of the four DOACs, namely dabigatran and rivaroxaban, we found successful phase III studies which led to the approval for the use in children. The results of these pivotal phase III studies allow to finally recommend rivaroxaban and dabigatran for the prophylaxis and treatment of thrombotic events in children.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis III: Interprofessional Care
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Factors Affecting Drug Response: Overview

